MicroRNA-146a Serves as a Biomarker for Adverse Prognosis of ST-Segment Elevation Myocardial Infarction

Objective. This study is aimed at exploring the underlying molecular mechanisms of ST-segment elevation myocardial infarction (STEMI) and provides potential clinical prognostic biomarkers for STEMI. Methods. The GSE60993 dataset was downloaded from the GEO database, and the differentially expressed...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Shengjue Xiao, Tongneng Xue, Qinyuan Pan, Yue Hu, Qi Wu, Qiaozhi Liu, Xiaotong Wang, Ailin Liu, Jie Liu, Hong Zhu, Yufei Zhou, Defeng Pan
Formato:	article
Lenguaje:	EN
Publicado:	Hindawi-Wiley 2021
Materias:	Therapeutics. Pharmacology RM1-950 Diseases of the circulatory (Cardiovascular) system RC666-701
Acceso en línea:	https://doaj.org/article/9570007275a745c5a5bad34200d758d0
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:9570007275a745c5a5bad34200d758d0
record_format	dspace
spelling	oai:doaj.org-article:9570007275a745c5a5bad34200d758d02021-11-08T02:35:39ZMicroRNA-146a Serves as a Biomarker for Adverse Prognosis of ST-Segment Elevation Myocardial Infarction1755-592210.1155/2021/2923441https://doaj.org/article/9570007275a745c5a5bad34200d758d02021-01-01T00:00:00Zhttp://dx.doi.org/10.1155/2021/2923441https://doaj.org/toc/1755-5922Objective. This study is aimed at exploring the underlying molecular mechanisms of ST-segment elevation myocardial infarction (STEMI) and provides potential clinical prognostic biomarkers for STEMI. Methods. The GSE60993 dataset was downloaded from the GEO database, and the differentially expressed genes (DEGs) between STEMI and control groups were screened. Enrichment analysis of the DEGs was subsequently performed using the DAVID database. A protein–protein interaction network was constructed, and hub genes were identified. The hub genes in patients were then validated by quantitative reverse transcription-PCR. Furthermore, hub gene-miRNA interactions were evaluated using the miRTarBase database. Finally, patient data on classical cardiovascular risk factors were collected, and plasma microRNA-146a (miR-146a) levels were detected. An individualized nomogram was constructed based on multivariate Cox regression analysis. Results. A total of 239 DEGs were identified between the STEMI and control groups. Expression of S100A12 and miR-146a was significantly upregulated in STEMI samples compared with controls. STEMI patients with high levels of miR-146a had a higher risk of major adverse cardiovascular events (MACEs) than those with low levels of miR-146a (log-rank P=0.034). Multivariate Cox regression analysis identified five statistically significant variables, including age, hypertension, diabetes mellitus, white blood cells, and miR-146a. A nomogram was constructed to estimate the likelihood of a MACE at one, two, and three years after STEMI. Conclusion. The incidence of MACEs in STEMI patients expressing high levels of miR-146a was significantly greater than in those expressing low levels. MicroRNA-146a can serve as a biomarker for adverse prognosis of STEMI and might function in its pathogenesis by targeting S100A12, which may exert its role via an inflammatory response. In addition, our study presents a valid and practical model to assess the probability of MACEs within three years of STEMI.Shengjue XiaoTongneng XueQinyuan PanYue HuQi WuQiaozhi LiuXiaotong WangAilin LiuJie LiuHong ZhuYufei ZhouDefeng PanHindawi-WileyarticleTherapeutics. PharmacologyRM1-950Diseases of the circulatory (Cardiovascular) systemRC666-701ENCardiovascular Therapeutics, Vol 2021 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Therapeutics. Pharmacology RM1-950 Diseases of the circulatory (Cardiovascular) system RC666-701
spellingShingle	Therapeutics. Pharmacology RM1-950 Diseases of the circulatory (Cardiovascular) system RC666-701 Shengjue Xiao Tongneng Xue Qinyuan Pan Yue Hu Qi Wu Qiaozhi Liu Xiaotong Wang Ailin Liu Jie Liu Hong Zhu Yufei Zhou Defeng Pan MicroRNA-146a Serves as a Biomarker for Adverse Prognosis of ST-Segment Elevation Myocardial Infarction
description	Objective. This study is aimed at exploring the underlying molecular mechanisms of ST-segment elevation myocardial infarction (STEMI) and provides potential clinical prognostic biomarkers for STEMI. Methods. The GSE60993 dataset was downloaded from the GEO database, and the differentially expressed genes (DEGs) between STEMI and control groups were screened. Enrichment analysis of the DEGs was subsequently performed using the DAVID database. A protein–protein interaction network was constructed, and hub genes were identified. The hub genes in patients were then validated by quantitative reverse transcription-PCR. Furthermore, hub gene-miRNA interactions were evaluated using the miRTarBase database. Finally, patient data on classical cardiovascular risk factors were collected, and plasma microRNA-146a (miR-146a) levels were detected. An individualized nomogram was constructed based on multivariate Cox regression analysis. Results. A total of 239 DEGs were identified between the STEMI and control groups. Expression of S100A12 and miR-146a was significantly upregulated in STEMI samples compared with controls. STEMI patients with high levels of miR-146a had a higher risk of major adverse cardiovascular events (MACEs) than those with low levels of miR-146a (log-rank P=0.034). Multivariate Cox regression analysis identified five statistically significant variables, including age, hypertension, diabetes mellitus, white blood cells, and miR-146a. A nomogram was constructed to estimate the likelihood of a MACE at one, two, and three years after STEMI. Conclusion. The incidence of MACEs in STEMI patients expressing high levels of miR-146a was significantly greater than in those expressing low levels. MicroRNA-146a can serve as a biomarker for adverse prognosis of STEMI and might function in its pathogenesis by targeting S100A12, which may exert its role via an inflammatory response. In addition, our study presents a valid and practical model to assess the probability of MACEs within three years of STEMI.
format	article
author	Shengjue Xiao Tongneng Xue Qinyuan Pan Yue Hu Qi Wu Qiaozhi Liu Xiaotong Wang Ailin Liu Jie Liu Hong Zhu Yufei Zhou Defeng Pan
author_facet	Shengjue Xiao Tongneng Xue Qinyuan Pan Yue Hu Qi Wu Qiaozhi Liu Xiaotong Wang Ailin Liu Jie Liu Hong Zhu Yufei Zhou Defeng Pan
author_sort	Shengjue Xiao
title	MicroRNA-146a Serves as a Biomarker for Adverse Prognosis of ST-Segment Elevation Myocardial Infarction
title_short	MicroRNA-146a Serves as a Biomarker for Adverse Prognosis of ST-Segment Elevation Myocardial Infarction
title_full	MicroRNA-146a Serves as a Biomarker for Adverse Prognosis of ST-Segment Elevation Myocardial Infarction
title_fullStr	MicroRNA-146a Serves as a Biomarker for Adverse Prognosis of ST-Segment Elevation Myocardial Infarction
title_full_unstemmed	MicroRNA-146a Serves as a Biomarker for Adverse Prognosis of ST-Segment Elevation Myocardial Infarction
title_sort	microrna-146a serves as a biomarker for adverse prognosis of st-segment elevation myocardial infarction
publisher	Hindawi-Wiley
publishDate	2021
url	https://doaj.org/article/9570007275a745c5a5bad34200d758d0
work_keys_str_mv	AT shengjuexiao microrna146aservesasabiomarkerforadverseprognosisofstsegmentelevationmyocardialinfarction AT tongnengxue microrna146aservesasabiomarkerforadverseprognosisofstsegmentelevationmyocardialinfarction AT qinyuanpan microrna146aservesasabiomarkerforadverseprognosisofstsegmentelevationmyocardialinfarction AT yuehu microrna146aservesasabiomarkerforadverseprognosisofstsegmentelevationmyocardialinfarction AT qiwu microrna146aservesasabiomarkerforadverseprognosisofstsegmentelevationmyocardialinfarction AT qiaozhiliu microrna146aservesasabiomarkerforadverseprognosisofstsegmentelevationmyocardialinfarction AT xiaotongwang microrna146aservesasabiomarkerforadverseprognosisofstsegmentelevationmyocardialinfarction AT ailinliu microrna146aservesasabiomarkerforadverseprognosisofstsegmentelevationmyocardialinfarction AT jieliu microrna146aservesasabiomarkerforadverseprognosisofstsegmentelevationmyocardialinfarction AT hongzhu microrna146aservesasabiomarkerforadverseprognosisofstsegmentelevationmyocardialinfarction AT yufeizhou microrna146aservesasabiomarkerforadverseprognosisofstsegmentelevationmyocardialinfarction AT defengpan microrna146aservesasabiomarkerforadverseprognosisofstsegmentelevationmyocardialinfarction
_version_	1718443209674194944

MicroRNA-146a Serves as a Biomarker for Adverse Prognosis of ST-Segment Elevation Myocardial Infarction

Ejemplares similares